Caligan Partners reports 10.3% stake in Amag Pharmaceuticals
In a regulatory filing, Caligan Partners said it believes Amag Pharmaceuticals shares are undervalued and represent an attractive investment opportunity. Caligan may consider, explore and/or develop plans and/or make proposals with respect to, among other things, potential changes in, the company's operations, management, organizational documents, the composition of the board, ownership, capital or corporate structure, dividend policy, and strategy and plans of the company, as well as a potential strategic review or sale process involving the company or certain of the company's businesses or assets, including transactions in which Caligan may seek to participate and potentially engage in. Caligan intends to communicate with Amag's management and board about a broad range of operational and strategic matters and to communicate with other shareholders or third parties, including potential acquirers, service providers and financing sources regarding the foregoing. Caligan may also take steps to explore and prepare for various plans and actions, and propose transactions, before forming an intention to engage in such plans or actions or proceed with such transactions.